Qutenza® (capsaicin) 8% patch

Patient Site | Full Prescribing Information | Register for Updates | Join Find A Doctor
Tell A Colleague | Print |
Physician Resources

Tell a Colleague About Qutenza®

To share information about Qutenza® with your colleagues, simply fill out the fields below, and we will send each colleague an e-mail on your behalf.

From:

Your name:
Enter your name

Your e-mail address:
Enter valid e-mail



To:

Note: We will not add your recipients to any mailing lists.
E-mail address(es) to send to: (enter at least one)

1)

2)

3)

4)

5)



Message:
Enter your text below that you would like your colleague(s) to receive, and a link to the page will be provided.




Send a copy to my e-mail.


   

NeurogesX and companies working with NeurogesX will not share the information you provide with any third parties.

Request Qutenza® TRAINING
Call 877-900-6479

Get Info

Order Qutenza®

Qutenza®

Support For Your Practice

Connect Now

Indication: Qutenza® (capsaicin) 8% patch is indicated for the management of neuropathic pain associated with postherpetic neuralgia.

IMPORTANT SAFETY INFORMATION

Only physicians or healthcare professionals under the close supervision of a physician are to administer Qutenza®.

Contraindications: None.

Warnings and Precautions:

  • Do not use on face or scalp.
  • Aerosolization of capsaicin can occur and inhalation may result in coughing or sneezing.
  • If skin not intended to be treated comes into contact with Qutenza®, clean area using Cleansing Gel.
  • Patients may experience substantial procedural pain. Prepare to treat pain with local cooling (such as a cold pack) and/or appropriate analgesic medication.
  • Transient increases in blood pressure may occur during and shortly after the Qutenza® treatment. In clinical trials, blood pressure changes were associated with treatment-related increases in pain. Monitor blood pressure and provide adequate support for treatment-related pain. Patients with unstable or poorly controlled hypertension or a recent history of cardiovascular or cerebrovascular events may be at an increased risk of adverse cardiovascular effects. Consider these factors prior to initiating Qutenza® treatment.

Adverse Reactions: In clinical trials, serious adverse reactions included application-associated pain and increase in blood pressure. The most common adverse reactions (≥ 5% and greater than control) were application-site erythema, application-site pain, application-site pruritus, and application-site papules.

For additional information, please click here for full Prescribing Information.

Patient Site| Contact Us|Site Map|Privacy Policy |Terms of Use|Full Prescribing Information| NeurogesX.com|Unsubscribe|Find A Doctor Opt-Out
NeurogesX - Changing the course of pain

©NeurogesX, Inc. 2010. All Rights Reserved. ®marks owned by NeurogesX, Inc. Q2010032-14 110453